Brilliant science is just the start. It does not necessarily lead to an innovative therapeutic intervention and a successful biotech company. Attracting and engaging with the right VCs and partners is critical if you are going to translate your science into an impactful patient solution. This forum will explore practical strategies to help you stand out from the crowd. Learn how to showcase your company as a differentiated investment opportunity for potential investors.
- What VCs are looking for in early-stage life science companies
- Making your company and asset(s) attractive: what’s important and what is not
- How you can create and drive value
- VCs as partners and how they can help with more than money
Michelle Scott, PhD, MBA, VP and Head, Biotech Development Solutions at Labcorp
She has over 25 years of experience in the pharmaceutical industry with a unique combination of strategic, medicines development, regulatory affairs, scientific, business development and management expertise. Michelle’s role at Labcorp mirrors the critical needs of biotech companies. She is responsible for leadership and successful implementation of innovative and strategic drug development solutions. Michelle provides direction and leadership of Biotech drug development, strategic partnering support with MarketPlace (Labcorp’s unique digital partnering platform) and heads up LabCorp’s BioFund, a
small venture fund designed to help early stage companies bridge funding gaps.
Shaan C. Gandhi, MD., DPhil, Director, Northpond Ventures
Shaan C. Gandhi is a Director at Northpond Ventures on the firm’s biotechnologies team. Shaan is a Board Director at Aro Biotherapeutics, CAMP4 Therapeutics, Candel Therapeutics (NASDAQ: CADL), DICE Therapeutics (NASDAQ: DICE), Garuda Therapeutics, Mestag Therapeutics, StrideBio, and Vigil Neuroscience. Previously, Shaan was a Principal at the Longwood Fund, where he created and invested in life sciences companies, including Pyxis Oncology (NASDAQ: PYXS), an antibody-drug conjugate and monoclonal antibody oncology company, which he co-founded and served as President. Prior to Longwood, he was an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine.